ATE241628T1 - Imidazo(5,1-f)(1,2,4)triazinderivate - Google Patents

Imidazo(5,1-f)(1,2,4)triazinderivate

Info

Publication number: ATE241628T1
Authority: AT; Austria
Prior art keywords: imidazo; triazine derivatives; het; curative; chem
Prior art date: 1999-10-11

Application number

AT00308914T

Other languages

English (en)

Inventor

Graham Nigel Maw

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-11

Filing date

2000-10-10

Publication date

2003-06-15

1999-10-11 Priority claimed from GBGB9924028.5A external-priority patent/GB9924028D0/en

2000-03-28 Priority claimed from GB0007345A external-priority patent/GB0007345D0/en

2000-10-10 Application filed by Pfizer filed Critical Pfizer

2003-06-15 Application granted granted Critical

2003-06-15 Publication of ATE241628T1 publication Critical patent/ATE241628T1/de

Links

AZTMMFCJOROKMO-UHFFFAOYSA-N imidazo[5,1-f][1,2,4]triazine Chemical class N1=CN=CC2=CN=CN21 AZTMMFCJOROKMO-UHFFFAOYSA-N 0.000 title 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 2
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
101150098694 PDE5A gene Proteins 0.000 abstract 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Compositions Of Macromolecular Compounds (AREA)

AT00308914T 1999-10-11 2000-10-10 Imidazo(5,1-f)(1,2,4)triazinderivate ATE241628T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9924028.5A GB9924028D0 (en)	1999-10-11	1999-10-11	Pharmaceutically active compounds
GB0007345A GB0007345D0 (en)	2000-03-28	2000-03-28	Pharmaceutically active compounds

Publications (1)

Publication Number	Publication Date
ATE241628T1 true ATE241628T1 (de)	2003-06-15

Family

ID=26243966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00308914T ATE241628T1 (de)	1999-10-11	2000-10-10	Imidazo(5,1-f)(1,2,4)triazinderivate

Country Status (11)

Country	Link
US (1)	US6503908B1 (de)
EP (1)	EP1092719B1 (de)
JP (1)	JP3549826B2 (de)
AT (1)	ATE241628T1 (de)
BR (1)	BR0004779A (de)
CA (1)	CA2323008C (de)
DE (1)	DE60002969T2 (de)
DK (1)	DK1092719T3 (de)
ES (1)	ES2199122T3 (de)
MX (1)	MXPA00009937A (de)
PT (1)	PT1092719E (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6362178B1 (en) *	1997-11-12	2002-03-26	Bayer Aktiengesellschaft	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
CO5180550A1 (es)	1999-04-19	2002-07-30	Smithkline Beecham Corp	Inhibidores de fab i
CO5370679A1 (es)	1999-06-01	2004-02-27	Smithkline Beecham Corp	Inhibidores fab 1
US6730684B1 (en) *	1999-10-08	2004-05-04	Affinium Pharmaceuticals, Inc.	Fab I inhibitors
ATE285821T1 (de) *	1999-10-08	2005-01-15	Affinium Pharm Inc	Fab i inhibitoren
US6762201B1 (en)	1999-10-08	2004-07-13	Affinium Pharmaceuticals, Inc.	Fab I inhibitors
IT1318674B1 (it) *	2000-08-08	2003-08-27	Nicox Sa	Faramaci per l'incontinenza.
WO2002013798A2 (en) *	2000-08-11	2002-02-21	Pfizer Limited	Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
US6548508B2 (en)	2000-10-20	2003-04-15	Pfizer, Inc.	Use of PDE V inhibitors for improved fecundity in mammals
US6794387B2 (en)	2001-03-28	2004-09-21	Pfizer Inc.	Pharmaceutically active compounds
GB0107751D0 (en) *	2001-03-28	2001-05-16	Pfizer Ltd	Pharmaceutically active compounds
CA2444597A1 (en) *	2001-04-06	2002-10-06	Affinium Pharmaceuticals, Inc.	Fab i inhibitors
PL363679A1 (en) *	2001-05-09	2004-11-29	Bayer Healthcare Ag	Novel use of 2-phenyl-substituted imidazotriazinones
GB0113343D0 (en) *	2001-06-01	2001-07-25	Bayer Ag	Novel Heterocycles 2
GB0113344D0 (en) *	2001-06-01	2001-07-25	Bayer Ag	Novel heterocycles 3
DE10135815A1 (de)	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
GB0202254D0 (en) *	2002-01-31	2002-03-20	Pfizer Ltd	Prevention of scarring
GB0209988D0 (en) *	2002-05-01	2002-06-12	Bayer Ag	Novel Heterocycles
DE10230605A1 (de) *	2002-07-08	2004-01-29	Bayer Ag	Substituierte Imidazotriazine
DE10232113A1 (de) *	2002-07-16	2004-01-29	Bayer Ag	Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US8133903B2 (en)	2003-10-21	2012-03-13	Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center	Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
EP1575951B1 (de) *	2002-12-06	2014-06-25	Debiopharm International SA	Heterozyclische verbindungen, verfahren zu deren herstellung und ihre verwendung als heilmittel
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
WO2004054560A1 (en)	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Alpha-2-delta ligand to treat lower urinary tract symptoms
US20050048573A1 (en) *	2003-02-03	2005-03-03	Plexxikon, Inc.	PDE5A crystal structure and uses
DE602004016831D1 (de)	2003-03-17	2008-11-13	Affinium Pharm Inc	Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
JP2006219374A (ja)	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) *	2003-07-07	2005-04-14	Plexxikon, Inc.	Ligand development using PDE4B crystal structures
ES2294543T3 (es)	2003-07-09	2008-04-01	The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal	Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
BRPI0506994A (pt)	2004-01-22	2007-07-03	Pfizer	derivados de triazol que inibem a atividade antagonista da vasopressina
US20050186275A1 (en) *	2004-02-23	2005-08-25	Standard Chem. & Pharm. Co. Ltd.	Sustained release tamsulosin formulations
DE102004023069A1 (de) *	2004-05-11	2005-12-08	Bayer Healthcare Ag	Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
EP2848614A3 (de) *	2004-06-04	2015-07-29	Debiopharm International SA	Acrylamidderivate und ihre Verwendung als Antibiotika
DE102004038328A1 (de) *	2004-08-06	2006-03-16	Bayer Healthcare Ag	Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
WO2006018088A1 (en) *	2004-08-19	2006-02-23	Switch Biotech Ag	Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders
ATE438403T1 (de) *	2004-08-19	2009-08-15	Switch Biotech Llc	Verwendung eines pde5-hemmers zur behandlung und vorbeugung von hypopigmentierungsstörungen
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
CA2598271A1 (en) *	2005-02-18	2006-08-24	Surface Logix, Inc.	Pharmacokinetically improved compounds
NZ560962A (en) *	2005-02-18	2011-12-22	Surface Logix Inc	Methods of making pharmacokinetically improved compounds using sarcosine functional residues or groups and pharmaceutical compositions comprising said compounds
DE102005009240A1 (de) *	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2006100557A1 (en)	2005-03-21	2006-09-28	Pfizer Limited	Substituted triazole derivatives as oxytocin antagonists
US20070004745A1 (en) *	2005-03-25	2007-01-04	Schering-Plough Corporation	Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
US20070010525A1 (en) *	2005-06-27	2007-01-11	Meyer Jackson	Method and compositions for modulating neuropeptide hormone secretion
US20090186896A1 (en) *	2005-09-29	2009-07-23	Bayer Healthcare Ag	PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
EP1973902A2 (de) *	2005-12-05	2008-10-01	Affinium Pharmaceuticals, Inc.	3-heterocyclylacrylamidverbindungen als fabi-inhibitoren und antibakterielle mittel
EP2687533B1 (de) *	2006-07-20	2017-07-19	Debiopharm International SA	Acrylamidderivate als FAB-I-Hemmer
WO2008098374A1 (en)	2007-02-16	2008-08-21	Affinium Pharmaceuticals, Inc.	Salts, prodrugs and polymorphs of fab i inhibitors
EP2167057A1 (de) *	2007-06-13	2010-03-31	Bayer HealthCare AG	Pde-hemmer zur behandlung von gehörschäden
HUE055286T2 (hu)	2011-04-08	2021-11-29	Janssen Sciences Ireland Unlimited Co	Pirimidinszármazékok vírusfertõzések kezelésére
RS57851B1 (sr)	2011-11-09	2018-12-31	Janssen Sciences Ireland Uc	Purinski derivati za tretman viralnih infekcija
SI2861608T1 (sl)	2012-06-19	2019-08-30	Debiopharm International Sa	Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
CA2874800C (en)	2012-07-13	2021-04-06	Janssen R&D Ireland	Macrocyclic purines for the treatment of viral infections
LT2906563T (lt)	2012-10-10	2018-06-11	Janssen Sciences Ireland Uc	Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
EP2925729B1 (de)	2012-11-16	2017-10-18	Janssen Sciences Ireland UC	Heterocyclische substituierte 2-amino-chinazolinderivate zur behandlung von virusinfektionen
WO2014128189A1 (en)	2013-02-21	2014-08-28	Janssen R&D Ireland	2-aminopyrimidine derivatives for the treatment of viral infections
AU2014242954B2 (en)	2013-03-29	2018-03-15	Janssen Sciences Ireland Uc	Macrocyclic deaza-purinones for the treatment of viral infections
SG11201509520QA (en)	2013-05-24	2015-12-30	Janssen Sciences Ireland Uc	Pyridone derivatives for the treatment of viral infections and further diseases
BR112015032546B1 (pt)	2013-06-27	2022-05-17	Janssen Sciences Ireland Uc	Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
KR102322425B1 (ko)	2013-07-30	2021-11-05	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
BR122023021456A2 (pt)	2016-02-26	2024-02-20	Debiopharm International S.A.	Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
AU2017289418B2 (en)	2016-07-01	2021-06-03	Janssen Sciences Ireland Unlimited Company	Dihydropyranopyrimidines for the treatment of viral infections
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
JP7274415B2 (ja)	2016-09-29	2023-05-16	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
TW202415645A (zh)	2018-03-01	2024-04-16	愛爾蘭商健生科學愛爾蘭無限公司	２，４－二胺基喹唑啉衍生物及其醫學用途
LT3923914T (lt)	2019-02-14	2023-07-25	Debiopharm International S.A.	Afabicino kompozicija, jos gamybos būdas
CN113939306B (zh)	2019-06-14	2024-07-19	德彪药业国际股份公司	用于治疗涉及生物膜的细菌感染的药物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6362178B1 (en) *	1997-11-12	2002-03-26	Bayer Aktiengesellschaft	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19827640A1 (de)	1998-06-20	1999-12-23	Bayer Ag	7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
EP1123296B1 (de)	1998-10-23	2003-09-17	Pfizer Limited	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen

2000
- 2000-10-06 US US09/685,160 patent/US6503908B1/en not_active Expired - Fee Related
- 2000-10-06 CA CA002323008A patent/CA2323008C/en not_active Expired - Fee Related
- 2000-10-10 AT AT00308914T patent/ATE241628T1/de not_active IP Right Cessation
- 2000-10-10 MX MXPA00009937A patent/MXPA00009937A/es active IP Right Grant
- 2000-10-10 ES ES00308914T patent/ES2199122T3/es not_active Expired - Lifetime
- 2000-10-10 DE DE60002969T patent/DE60002969T2/de not_active Expired - Fee Related
- 2000-10-10 DK DK00308914T patent/DK1092719T3/da active
- 2000-10-10 EP EP00308914A patent/EP1092719B1/de not_active Expired - Lifetime
- 2000-10-10 PT PT00308914T patent/PT1092719E/pt unknown
- 2000-10-11 BR BR0004779-1A patent/BR0004779A/pt not_active IP Right Cessation
- 2000-10-11 JP JP2000310580A patent/JP3549826B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60002969D1 (de)	2003-07-03
DK1092719T3 (da)	2003-08-25
BR0004779A (pt)	2001-05-29
PT1092719E (pt)	2003-08-29
MXPA00009937A (es)	2002-10-23
EP1092719A3 (de)	2001-09-26
JP3549826B2 (ja)	2004-08-04
CA2323008A1 (en)	2001-04-11
JP2001151778A (ja)	2001-06-05
ES2199122T3 (es)	2004-02-16
CA2323008C (en)	2005-07-12
EP1092719A2 (de)	2001-04-18
DE60002969T2 (de)	2004-01-22
US6503908B1 (en)	2003-01-07
EP1092719B1 (de)	2003-05-28

Legal Events

Date

Code

Title

Description

2003-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1092719

Country of ref document: EP

2007-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE241628T1 (de)	2003-06-15	Imidazo(5,1-f)(1,2,4)triazinderivate
GB9823103D0 (en)	1998-12-16	Pharmaceutically active compounds
TR200200954T2 (tr)	2002-09-23	Fosfodiesteraz inhibitörleri olarak 5-(2-ikame edilmiş-5-heterosiklilsülfonilpirid-3-il)- dihidropirazolo[4,3- D]pirimidin-7-onlar.
DE60202134D1 (en)	2005-01-05	Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
ATE298238T1 (de)	2005-07-15	Pyrazolo(4,3-d)pyrimidinon-verbindungen als cgmp pde-inhibitoren
DK1123296T3 (da)	2003-12-08	Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse
CA2287552A1 (en)	2000-04-23	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
CA2322900A1 (en)	2001-04-11	2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
NO995211D0 (no)	1999-10-25	Pyrazolpyrimidinoner som hemmer cyklisk guanosin-3',5'-monofosfatfosfodiesterase type 5 (cGMP PDE5), for behandling av seksuell dysfunksjon
MXPA03011906A (es)	2004-03-26	Derivados de imidazo' 1,2-a-piridina para la profilaxis y el tratamiento de infecciones virales por herpes.
ATE79380T1 (de)	1992-08-15	2-substituierte-e-kondensierte(1,2,4>triazolo(1,5-c>pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
SG70625A1 (en)	2000-02-22	1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines
CA2413510A1 (en)	2002-01-03	Condensed pyrazindione derivatives
WO2002079203A8 (en)	2002-11-21	Imidazo-triazine derivatives as pde 5 inhibitors
AP2002002462A0 (en)	2002-06-30	Pharmaceutically active compounds.
ECSP003706A (es)	2002-05-23	Compuestos farmaceuticamente activos